BG99141A - Моноклонално антитяло срещу рецептора за човешкиинтерферон - Google Patents

Моноклонално антитяло срещу рецептора за човешкиинтерферон Download PDF

Info

Publication number
BG99141A
BG99141A BG99141A BG9914194A BG99141A BG 99141 A BG99141 A BG 99141A BG 99141 A BG99141 A BG 99141A BG 9914194 A BG9914194 A BG 9914194A BG 99141 A BG99141 A BG 99141A
Authority
BG
Bulgaria
Prior art keywords
human
cells
ifn
monoclonal antibody
interferon
Prior art date
Application number
BG99141A
Other languages
Bulgarian (bg)
English (en)
Inventor
Patrick Benoit
Francois Meyer
Debborah Maguire
Ivan Plavec
Michael Tovey
Original Assignee
Laboratore Europeen De Biotechnologie S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratore Europeen De Biotechnologie S.A. filed Critical Laboratore Europeen De Biotechnologie S.A.
Publication of BG99141A publication Critical patent/BG99141A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BG99141A 1992-03-31 1994-10-28 Моноклонално антитяло срещу рецептора за човешкиинтерферон BG99141A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92400902A EP0563487A1 (fr) 1992-03-31 1992-03-31 Anticorps monoclonaux contre le récepteur d'interféron avec une activité contre l'interféron du type I
PCT/EP1993/000770 WO1993020187A1 (fr) 1992-03-31 1993-03-30 Anticorps monoclonaux dresses contre le recepteur d'interferon et dotes d'une activite neutralisante dirigee contre l'interferon de type i

Publications (1)

Publication Number Publication Date
BG99141A true BG99141A (bg) 1995-07-28

Family

ID=8211644

Family Applications (1)

Application Number Title Priority Date Filing Date
BG99141A BG99141A (bg) 1992-03-31 1994-10-28 Моноклонално антитяло срещу рецептора за човешкиинтерферон

Country Status (18)

Country Link
US (5) US5919453A (fr)
EP (3) EP0563487A1 (fr)
JP (2) JP3836500B2 (fr)
AT (2) ATE241008T1 (fr)
AU (2) AU679909B2 (fr)
BG (1) BG99141A (fr)
CA (1) CA2133106C (fr)
CZ (1) CZ236994A3 (fr)
DE (2) DE69332997T2 (fr)
DK (2) DK0633931T3 (fr)
ES (2) ES2290241T3 (fr)
FI (1) FI944509L (fr)
HU (1) HUT69995A (fr)
NO (1) NO943625L (fr)
NZ (1) NZ251343A (fr)
PT (2) PT633931E (fr)
RU (1) RU94045826A (fr)
WO (1) WO1993020187A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563487A1 (fr) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Anticorps monoclonaux contre le récepteur d'interféron avec une activité contre l'interféron du type I
WO1995007716A1 (fr) * 1993-09-17 1995-03-23 Laboratoire Europeen De Biotechnologie S.A. Composition pharmaceutique comprenant des anticorps monoclonaux diriges contre le recepteur d'interferon et dotes d'une activite neutralisante a l'egard de l'interferon de type i
IL118096A0 (en) * 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
US6713609B1 (en) 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
CN1068524C (zh) * 1997-06-23 2001-07-18 叶庆炜 一种治疗顽症牛皮癣的药物
US6376067B1 (en) * 1998-12-21 2002-04-23 Mitsubishi Polyester Film, Llc Silicone coated film with back side slip control coating and method of controlling slip of such film
GB0001712D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic peptides
AU2002246955B2 (en) * 2001-01-09 2007-03-22 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
AU2007202840B2 (en) * 2001-01-09 2011-07-28 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
AU2007203559B2 (en) * 2003-04-23 2010-09-02 E. R. Squibb & Sons, L.L.C. Compositions and methods for the therapy of inflammatory bowel disease
EP1631590B1 (fr) * 2003-04-23 2011-07-27 Medarex, Inc. Anticorps humanises du recepteur 1 alpha d'interferon (ifnar-1)
DK1631312T3 (da) * 2003-04-23 2009-01-19 Medarex Inc Sammensætning og fremstillingsmåde til behandling af inflammatorisk tarmsygdom
ES2399050T3 (es) 2003-12-10 2013-03-25 Medarex, Inc. Anticuerpos contra interferón alfa y sus usos
EP1789453A2 (fr) * 2004-05-18 2007-05-30 Genentech, Inc. Principaux variants de la proteine de coque majeure du virus m13 pour affichage c-terminal et bi-terminal d'une proteine heterologue
KR20150041193A (ko) 2004-06-21 2015-04-15 메다렉스, 엘.엘.시. 인터페론 알파 수용체 1 항체 및 그의 용도
EP1796722A1 (fr) * 2004-10-07 2007-06-20 Universität Zürich Agents bloquants de l'interferon de type 1 dans la prevention et le traitement du psoriasis
US7888481B2 (en) * 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
JP5837730B2 (ja) * 2005-02-10 2015-12-24 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗インターフェロンアルファモノクローナル抗体及び使用方法
US20070081995A1 (en) * 2005-06-22 2007-04-12 Genentech, Inc. Methods and compositions for targeting IFNAR2
EP2687232A1 (fr) 2006-12-06 2014-01-22 MedImmune, LLC Procédés de traitement du lupus érythémateux systémique
US8685400B2 (en) 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
CN101952454B (zh) 2008-02-08 2014-06-04 米迪缪尼有限公司 具有减弱的Fc配体亲和性的抗IFNAR1抗体
CN102083859B (zh) 2008-05-07 2014-09-17 阿哥斯医疗公司 人源化抗人干扰素-α抗体
CA2791962A1 (fr) * 2010-03-01 2011-09-09 Alexion Pharmaceuticals, Inc. Methodes et compositions pour le traitement de la maladie de degos
WO2013134146A1 (fr) * 2012-03-07 2013-09-12 The Regents Of The University Of California Procédés et compositions pour le traitement d'infections virales par blocage de l'activité de l'interféron de type i
AU2017290389B2 (en) 2016-07-01 2024-09-26 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
US11136399B2 (en) 2016-07-14 2021-10-05 Institute Of Biophysics, Chinese Academy Of Sciences Type I interferon receptor antibody and use thereof
US10947295B2 (en) 2017-08-22 2021-03-16 Sanabio, Llc Heterodimers of soluble interferon receptors and uses thereof
EP3917965A4 (fr) * 2019-01-31 2023-03-08 Immunecent Biotechnology, Inc. Nouveaux anticorps anti-ifnar1
EP4393937A4 (fr) 2021-08-26 2025-12-31 Duality Biologics Shanghai Co Ltd Composé stéroïde et conjugué de celui-ci
CN115028730B (zh) * 2022-05-17 2022-11-08 诺赛联合(北京)生物医学科技有限公司 一种成体干细胞衍生的类器官制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953132A (en) 1955-10-27 1960-09-20 Baxter Laboratories Inc Parenteral solution equipment
US3066671A (en) 1959-10-27 1962-12-04 Milton J Cohen Disposable additive container
US3608550A (en) 1969-05-07 1971-09-28 Becton Dickinson Co Transfer needle assembly
BE791340A (fr) 1972-01-06 1973-03-01 Becton Dickinson Co Nouveaux procede et appareil de prelevement de culture et d'identification de micro-organismes des humeurs
US4024857A (en) 1974-12-23 1977-05-24 Becton, Dickinson And Company Micro blood collection device
US4300404A (en) 1977-12-01 1981-11-17 Becton, Dickinson And Company Liquid specimen container
US4116066A (en) 1977-12-12 1978-09-26 Becton, Dickinson And Company Specimen sampler cup
US5516515A (en) * 1986-02-05 1996-05-14 Interferon Sciences, Inc. Separation of alpha interferon receptor proteins and antibodies therefor
IL88377A (en) * 1988-11-14 1996-09-12 Yeda Res & Dev Cloning and expression of a protein which modulates cellular response to type I interferon
US5889151A (en) * 1989-10-20 1999-03-30 Societe Leb-Tech Purified human alpha interferon receptor
FR2653445B1 (fr) * 1989-10-20 1994-07-29 Centre Nat Rech Scient Fragment d'adnc codant pour le gene du recepteur de l'interferon alpha et procede de preparation d'une proteine correspondante.
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
FR2657881A1 (fr) * 1990-02-05 1991-08-09 Europ Biotechnologie Lab Nouveaux polypeptides hydrosolubles, sequences d'adn, nouvelles cellules, procede de preparation, applications et compositions renfermant lesdits polypeptides.
IL99232A0 (en) * 1990-08-20 1992-07-15 Univ Columbia Methods for producing rna viruses from cdna
AU653937B2 (en) * 1991-04-17 1994-10-20 Medisup International N.V. Water-soluble polypeptides having high affinity for interferons alpha and beta
EP0563487A1 (fr) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Anticorps monoclonaux contre le récepteur d'interféron avec une activité contre l'interféron du type I
CA2142007C (fr) * 1992-08-11 2007-10-30 Robert Glen Urban Peptides immunomodulateurs
DE69322289T2 (de) * 1992-12-29 1999-05-20 Genentech, Inc., South San Francisco, Calif. Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
JP4001379B2 (ja) * 1994-03-07 2007-10-31 インペリアル カレッジ オブ サイエンス，テクノロジー アンド メディシン ウィルス感染を治療する薬剤の調製におけるインターフェロンのサブタイプの使用
IL118096A0 (en) * 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor

Also Published As

Publication number Publication date
EP1329459B1 (fr) 2007-07-25
RU94045826A (ru) 1996-11-10
JP3836500B2 (ja) 2006-10-25
CZ236994A3 (en) 1995-02-15
DE69334158T2 (de) 2008-04-10
FI944509A0 (fi) 1994-09-29
US20070128701A1 (en) 2007-06-07
NO943625L (no) 1994-11-11
ES2199941T3 (es) 2004-03-01
PT633931E (pt) 2003-09-30
EP1329459A2 (fr) 2003-07-23
AU2349697A (en) 1997-07-24
DK0633931T3 (da) 2003-09-15
DE69332997T2 (de) 2004-05-19
DE69334158D1 (de) 2007-09-06
US5919453A (en) 1999-07-06
WO1993020187A1 (fr) 1993-10-14
EP0633931A1 (fr) 1995-01-18
US20040191840A1 (en) 2004-09-30
EP1329459A3 (fr) 2003-09-10
US6787634B2 (en) 2004-09-07
AU679909B2 (en) 1997-07-17
US20020055492A1 (en) 2002-05-09
US7465451B2 (en) 2008-12-16
CA2133106A1 (fr) 1993-10-14
NZ251343A (en) 1997-07-27
DE69332997D1 (de) 2003-06-26
FI944509A7 (fi) 1994-11-29
CA2133106C (fr) 2009-06-30
US20080226647A1 (en) 2008-09-18
NO943625D0 (no) 1994-09-29
AU3890793A (en) 1993-11-08
ATE241008T1 (de) 2003-06-15
JPH07505526A (ja) 1995-06-22
EP0563487A1 (fr) 1993-10-06
HUT69995A (en) 1995-09-28
HU9402823D0 (en) 1995-01-30
ES2290241T3 (es) 2008-02-16
FI944509L (fi) 1994-11-29
DK1329459T3 (da) 2007-11-26
JP2006089494A (ja) 2006-04-06
PT1329459E (pt) 2007-11-07
US7179465B2 (en) 2007-02-20
EP0633931B1 (fr) 2003-05-21
ATE368055T1 (de) 2007-08-15
AU706473B2 (en) 1999-06-17

Similar Documents

Publication Publication Date Title
US12006361B2 (en) Albumin binding domain fusion proteins
RU2135584C1 (ru) Гомодимер р40 интерлейкина-12
US7179465B2 (en) Monoclonal antibodies against the interferon receptor, with neutralizing activity against type 1 interferon
JP4099119B2 (ja) 表面複合リンホトキシン
JP4308322B2 (ja) インターフェロンアルファ／ベータ受容体に対する抗体
AU2033100A (en) Humanized antibodies to gamma-interferon
AU676325B2 (en) Receptors of interleukin-12 and antibodies
JPH11501283A (ja) Ｉ型インターフェロンに対する中和活性を有する、インターフェロンレセプターに対するモノクローナル抗体を含んでなる医薬組成物
KR100382628B1 (ko) 인터페론α/β결합단백질과이의제조및용도
JPH1070986A (ja) ヒトＴｈ１特異的タンパク質及びこれをコードする遺伝子、並びにこれに関連する形質転換体、組換えベクター及び抗体
JPH0767689A (ja) 抗ｌｄ７８ポリペプチドモノクローン抗体
Steinmann et al. Low incidence of antibody formation due to long-term interferon-α2c treatment of cancer patients
Andersson et al. Application of four anti-human interferon-α monoclonal antibodies for immunoassay and comparative analysis of natural interferon-α mixtures
Fultz et al. Interferon α-induced changes in FcγR-specific mRNA expression and isotype-specific, FcγR-mediated phagocytosis in C3H/OuJ (Lpsn) and C3H/HeJ (Lpsd) macrophages
HK40126456A (en) Albumin binding domain fusion proteins
Vanc et al. The Carboxyterminal Domains of Human IFN-α2 and IFN-α8 Are Antigenically Homologous
WO9308278 Pharmaceutical applications
IE19990005A1 (en) Monoclonal antibodies directed to the cytotoxic lymphocyte maturation factor